Cubist Pharmaceuticals PT Raised to $97.00
The firm currently has a "buy" rating on the stock. Mizuho's price target would indicate a potential upside of 26.66% from the stock's previous close.
Cubist Pharmaceuticals Given "Neutral" Rating at Zacks
's stock had its "neutral" rating restated by Zacks in a report released on Tuesday, ARN reports.
Cubist announces EMA acceptance of Tedizolid MAA for review
Cubist announces EMA acceptance of Tedizolid MAA for review Cubist Pharmaceuticals announced that the European Medicines Agency has accepted for review the company's Marketing Authorization Application, or MAA, for its investigational antibiotic tedizolid phosphate.
Moody's sees revenue ramp, not cliff, from biosimilar competition
A recent report from Moody's says launches of biosimilars - generic versions of complex biologics drugs - in the U.S. are likely at least three years away.
Cubist Pharmaceuticals CEO Sells $235,267 in Stock
Cubist Pharmaceuticals CEO Michael W. Bonney sold 3,112 shares of the company's stock in a transaction dated Thursday, February 20th.
Cubist & Cambridge Science Festival Launch "Germ Challenge" Science Contest
LEXINGTON, Mass. & CAMBRIDGE, Mass. -- -- Cambridge Science Festival and Cubist Pharmaceuticals, Inc. today launched the 2014 "Germ Challenge," a contest designed to engage young people in science by inviting them to create educational and creative videos that demonstrate their knowledge of germs and their ability to communicate scientific concepts ... (more)